* Intra-Cellular Therapies Inc reported a quarterly adjusted loss of 25 cents per share for the quarter ended September 30, identical to the same quarter last year. The mean expectation of fifteen analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -33 cents to -9 cents per share.
* Revenue rose 39% to $175.38 million from a year ago; analysts expected $172.35 million.
* Intra-Cellular Therapies Inc's reported EPS for the quarter was a loss of 25 cents.
* The company reported a quarterly loss of $26.32 million.
* Intra-Cellular Therapies Inc shares had risen by 4.9% this quarter and gained 7.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 39.1% in the last three months.
* In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Intra-Cellular Therapies Inc is $95.00 This summary was machine generated from LSEG data October 30 at 03:21 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.20 -0.25 Missed
Jun. 30 2024 -0.19 -0.16 Beat
Mar. 31 2024 -0.32 -0.16 Beat
Dec. 31 2023 -0.44 -0.30 Beat
Comments